PIPELINE
Pipeline
OBPharm is advancing a biomarker-driven pipeline of peptide and monoclonal antibody therapeutics for obesity and obesity-associated cardiovascular–kidney–metabolic (CKM) disease. Our model is intentionally translation-first: we start from mechanism-linked signals, design for developability, and progress partner-ready programs with an IND-oriented path in mind.
We apply a stage-gated process that connects mechanistic discovery to clinical endpoints. The output isn’t just “a target”—it’s a coherent package: what to build, how to test it, and which biomarkers prove the story.
Across peptide and mAb programs, we combine proprietary enabling technologies with rigorous biomarker strategy. We share full datasets, protocols, and timelines under CDA for qualified partners.
Partnering inquiries welcome.
PROGRAMS
Two lead programs in development
OB001 is a peptide program derived from adiponectin biology. OB002 is a monoclonal antibody program aimed at a biomarker-linked inflammatory axis in obesity-associated cardiovascular disease.
We are open to licensing and strategic collaborations across preclinical development and clinical-stage execution.